Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Current Assets (2018 - 2026)

TransMedics has reported Current Assets over the past 8 years, most recently at $637.8 million for Q4 2025.

  • For Q4 2025, Current Assets rose 28.27% year-over-year to $637.8 million; the TTM value through Dec 2025 reached $637.8 million, up 28.27%, while the annual FY2025 figure was $637.8 million, 28.27% up from the prior year.
  • Current Assets for Q4 2025 was $637.8 million at TransMedics, up from $613.0 million in the prior quarter.
  • Over five years, Current Assets peaked at $662.7 million in Q2 2023 and troughed at $95.1 million in Q2 2022.
  • A 5-year average of $374.9 million and a median of $490.4 million in 2024 define the central range for Current Assets.
  • Biggest five-year swings in Current Assets: fell 29.57% in 2022 and later skyrocketed 596.7% in 2023.
  • Year by year, Current Assets stood at $118.7 million in 2021, then surged by 112.54% to $252.3 million in 2022, then surged by 102.4% to $510.7 million in 2023, then decreased by 2.63% to $497.2 million in 2024, then grew by 28.27% to $637.8 million in 2025.
  • Business Quant data shows Current Assets for TMDX at $637.8 million in Q4 2025, $613.0 million in Q3 2025, and $558.1 million in Q2 2025.